R-Pharm Import-Substitutes German Erbitux — Drug for Head and Neck Cancer Therapy
The Ministry of Health of the Russian Federation has...
Petrovax Pharm Investments in Meningitis Vaccine Production Exceed 3 Billion Rubles
Biopharmaceutical company Petrovax Pharm has announced receiving an expanded...
Ellara Prepares to Launch Unique Peptide Synthesis Facility
Pharmaceutical company Ellara is completing preparations for the opening...
GMP Registry: New Certificates Issued and Refusals in January 2026
On January 26, the Ministry of Industry and Trade...
First Issued GMP Certificates and Refusals in 2026
January 2026 was marked by high regulatory activity: the...
Trump Launches TrumpRx: A Blow to Big Pharma or Pre-Election Hype?
President Donald Trump officially launched the TrumpRx.gov platform on...
WHO Issues Global Guidelines on the Use of “Weight Loss Shots”
The World Health Organization (WHO) has for the first...
Big Pharma Companies Expand in China: Investment Overview for 2026
By 2026, China is completing its transformation from a...
EU Adopts New Mandatory GMP Regulations for Veterinary Medicinal Products
In October 2025, the European Commission published new Implementing...
Global Pharma 2026: USA Dictates Prices, Europe Loses Leadership, Asia Booms
The global pharmaceutical industry is entering a correction phase....
EMA and PIC/S Tighten Control Over Active Pharmaceutical Substance Production
The European Medicines Agency (EMA), in collaboration with the...
What Happens in 2031? Regulator Sets “Deadline” for EAEU Veterinary Drug Rules
Since March 2024, supranational rules for the circulation of...
Transition to EAEU Standards: GMP Certification Rules for Veterinary Drugs are Changing
A draft Decree of the Government of the Russian...
EU Adopts New Mandatory GMP Regulations for Veterinary Medicinal Products
In October 2025, the European Commission published new Implementing...
Vet Pharma Under Digital Surveillance: “Chestny Znak” Exposes 950 Unlicensed Sellers
The Russian veterinary drug market is shifting to a...
SUSU Scientists Synthesize a Selective Anti-Anxiety Molecule
Researchers at South Ural State University (SUSU) have discovered...
Neural Network Breakthrough: FDA Approves Trials for AI-Created Parkinson’s Drug
January 23, 2026, became a landmark date for digital...
Good AI Practice: EMA and FDA Establish 10 Global Principles
Global regulators are setting a unified standard for the...
Eli Lilly and NVIDIA Open $1B AI R&D Center for Molecule Generation
Eli Lilly and NVIDIA have announced a major partnership...
OpenAI Enters Healthcare Market with ChatGPT Health and Enterprise Clinical Platform
OpenAI has officially announced its expansion into the healthcare...
R-Pharm Import-Substitutes German Erbitux — Drug for Head and Neck Cancer Therapy
The Ministry of Health of the Russian Federation has...
Petrovax Pharm Investments in Meningitis Vaccine Production Exceed 3 Billion Rubles
Biopharmaceutical company Petrovax Pharm has announced receiving an expanded...
Ellara Prepares to Launch Unique Peptide Synthesis Facility
Pharmaceutical company Ellara is completing preparations for the opening...
GMP Registry: New Certificates Issued and Refusals in January 2026
On January 26, the Ministry of Industry and Trade...
First Issued GMP Certificates and Refusals in 2026
January 2026 was marked by high regulatory activity: the...
Trump Launches TrumpRx: A Blow to Big Pharma or Pre-Election Hype?
President Donald Trump officially launched the TrumpRx.gov platform on...
WHO Issues Global Guidelines on the Use of “Weight Loss Shots”
The World Health Organization (WHO) has for the first...
Big Pharma Companies Expand in China: Investment Overview for 2026
By 2026, China is completing its transformation from a...
EU Adopts New Mandatory GMP Regulations for Veterinary Medicinal Products
In October 2025, the European Commission published new Implementing...
Global Pharma 2026: USA Dictates Prices, Europe Loses Leadership, Asia Booms
The global pharmaceutical industry is entering a correction phase....
EMA and PIC/S Tighten Control Over Active Pharmaceutical Substance Production
The European Medicines Agency (EMA), in collaboration with the...
What Happens in 2031? Regulator Sets “Deadline” for EAEU Veterinary Drug Rules
Since March 2024, supranational rules for the circulation of...
Transition to EAEU Standards: GMP Certification Rules for Veterinary Drugs are Changing
A draft Decree of the Government of the Russian...
EU Adopts New Mandatory GMP Regulations for Veterinary Medicinal Products
In October 2025, the European Commission published new Implementing...
Vet Pharma Under Digital Surveillance: “Chestny Znak” Exposes 950 Unlicensed Sellers
The Russian veterinary drug market is shifting to a...
SUSU Scientists Synthesize a Selective Anti-Anxiety Molecule
Researchers at South Ural State University (SUSU) have discovered...
Neural Network Breakthrough: FDA Approves Trials for AI-Created Parkinson’s Drug
January 23, 2026, became a landmark date for digital...
Good AI Practice: EMA and FDA Establish 10 Global Principles
Global regulators are setting a unified standard for the...
Eli Lilly and NVIDIA Open $1B AI R&D Center for Molecule Generation
Eli Lilly and NVIDIA have announced a major partnership...
OpenAI Enters Healthcare Market with ChatGPT Health and Enterprise Clinical Platform
OpenAI has officially announced its expansion into the healthcare...
PHARMPROM is a premier digital resource for the pharmaceutical sector, combining breaking news, deep insights, and key market events. We cover the entire product lifecycle—from R&D and manufacturing to distribution—in strict accordance with Good Pharmaceutical Practices (GxP).
Disclaimer All content on pharmprom.net is for informational purposes only and does not constitute medical advice. The materials are intended exclusively for industry professionals and are not addressed to the general public.
Headlines
A Pharma Plant Within University Walls: PSU Launches Drug Production Based on Spruce Cones
Perm State University (PSU) is moving from theory to...
GMP Registry Update: New Certificate Issuances and Refusals in Early February 2026
The Ministry of Industry and Trade of the Russian...
EMA and PIC/S Tighten Control Over Active Pharmaceutical Substance Production
The European Medicines Agency (EMA), in collaboration with the...
The Pfizer Case: Will FAS Use an Enforcement Mechanism for Intellectual Property Rights in the Pharma Market?
The Supreme Court of the Russian Federation has accepted...
